Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, Monaco C, Gasparini C, Sacre S, Lundberg A, Paleolog E, Horwood N J, Brennan F M, Foxwell B M J
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Charing Cross Hospital Campus, Arthritis Research Campaign Building, 1 Aspenlea Road, London W6 8LH, UK.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii13-8. doi: 10.1136/ard.61.suppl_2.ii13.
There is increasing evidence that NF-kappaB is a major, if not the major transcription factor regulating inflammation and immunity. While this implies that blocking NF-kappaB might be therapeutically beneficial, it raises clear questions regarding the balance between efficacy and safety. In this brief review we discuss the effects of NF-kappaB blockade in rheumatoid arthritis, inflammation and immunity, and consider possible therapeutic targets within the NF-kappaB family.
越来越多的证据表明,核因子-κB(NF-κB)即便不是调节炎症和免疫的主要转录因子,也是主要转录因子之一。虽然这意味着阻断NF-κB可能具有治疗益处,但这也引发了关于疗效和安全性平衡的明确问题。在这篇简短的综述中,我们讨论了NF-κB阻断在类风湿性关节炎、炎症和免疫中的作用,并考虑了NF-κB家族内可能的治疗靶点。